Have a feature idea you'd love to see implemented?
Let us know!
MNOV Medicinova Inc
Price (delayed)
$2
Market cap
$98.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.21
Enterprise value
$56.01M
MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S.
Highlights
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Medicinova's gross profit has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of MNOV
Market
Valuations
Earnings
Shares outstanding
49.05M
Market cap
$98.09M
Enterprise value
$56.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$10.29M
EBITDA
-$10.09M
Free cash flow
-$9.21M
Per share
Balance sheet
Liquidity
EPS
-$0.21
Free cash flow per share
-$0.19
Book value per share
$1.12
Revenue per share
$0
TBVPS
$0.99
Total assets
$58.12M
Total liabilities
$3.05M
Debt
$201,976
Equity
$55.07M
Working capital
$40.67M
Debt to equity
0
Current ratio
16.66
Quick ratio
16.28
Net debt/EBITDA
4.17
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-16.6%
Return on equity
-17.5%
Return on invested capital
-284.4%
Return on capital employed
-18.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNOV stock price
How has the Medicinova stock price performed over time
Intraday
2.56%
1 week
9.59%
1 month
12.36%
1 year
7.53%
YTD
33.33%
QTD
-4.76%
Financial performance
How have Medicinova's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.51M
Net income
-$10.29M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Medicinova's gross profit has shrunk by 100% QoQ and by 100% YoY
MNOV's net income is down by 26% from the previous quarter and by 8% YoY
The operating income is down by 23% since the previous quarter and by 4% year-on-year
Growth
What is Medicinova's growth rate over time
Valuation
What is Medicinova stock price valuation
P/E
N/A
P/B
1.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MNOV's EPS is down by 31% since the previous quarter and by 11% year-on-year
The P/B is 27% higher than the last 4 quarters average of 1.4 but 15% lower than the 5-year quarterly average of 2.1
The equity has declined by 15% year-on-year and by 4.1% since the previous quarter
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Efficiency
How efficient is Medicinova business performance
Medicinova's return on equity has decreased by 31% QoQ and by 23% YoY
MNOV's ROIC is down by 31% QoQ
The ROA fell by 31% QoQ and by 23% YoY
Dividends
What is MNOV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNOV.
Financial health
How did Medicinova financials performed over time
MNOV's total assets is down by 15% year-on-year and by 3.8% since the previous quarter
The quick ratio has contracted by 13% YoY and by 8% from the previous quarter
The debt is 100% less than the equity
The equity has declined by 15% year-on-year and by 4.1% since the previous quarter
The debt has grown by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.